Search

everythinglearnresearchcommunity

for

Search:↓

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Thyroid hormones and androgens affect gene expression in frog reproductive organs differently between males and females.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Hormone therapies like birth control pills and spironolactone are safe and effective for treating women's adult acne.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

PTHrP is higher in certain dog tumors and may act as a local growth factor.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Parathyroid hormones are important for hair growth, but their use in treating hair loss from chemotherapy is still uncertain.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

Gender affects hair and scalp characteristics, with differences in hormone responses, graying patterns, and trace metals.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Intersex frogs have different brain gene activity related to sex and thyroid hormones.

High leptin levels may promote skin cancer and inflammation, suggesting potential for leptin-targeted therapies.

Many young women with breast cancer experience poor quality of life, especially in sexual health and hair loss, but future outlook improves over time.

The effects of estrogen on human scalp hair growth are unclear and need more research.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

Activating NRF2 might help treat hair disorders by improving antioxidant defenses.